Literature DB >> 15660268

Biochemical and immunohistochemical analysis of glycosaminoglycans in inflamed and non-inflamed intestinal mucosa of patients with Crohn's disease.

Celso L R Belmiro1, Heitor S P Souza, Celeste C S Elia, Morgana T L Castelo-Branco, Flavia R Silva, Rosane L Machado, Mauro S G Pavão.   

Abstract

OBJECTIVES: Changes in extracellular matrix glycosaminoglycans (GAGs) of the intestinal mucosa have been associated with inflammatory bowel disease. The aim of the present study was to follow the changes in GAGs metabolism during the progression from non-inflamed to inflamed intestinal colon of patients with Crohn's disease (CD), using direct biochemical analysis and specific immunohistochemistry against chondroitin/dermatan sulfate and heparan sulfate. DESIGN AND METHODS: The content of GAGs from inflamed and non-inflamed colon of eight patients with active CD was estimated by uronic acid per dry weight of tissue and analyzed by agarose gel electrophoresis and ion-exchange chromatography. Intestinal sections were stained using antibodies against dermatan sulfate/chondroitin 4-sulfate (DS/CS), heparan sulfate (HS), and ICAM-1 (CD54), and analyzed by confocal microscopy.
RESULTS: There was a reduction in the amount of GAGs in the non-inflamed colon of patients with CD. In the inflamed colon, HS, CS and DS showed increased concentrations compared with the non-inflamed colon. GAGs showed a diffuse distribution in the lamina propria and in the basement membrane of both inflamed and non-inflamed mucosa of patients with CD.
CONCLUSION: We observed a marked reduction in GAGs with altered patterns of distribution in the non-inflamed colon of patients with CD. The increase in the synthesis of GAGs observed in the inflamed colon may be a compensatory mechanism for the restoration of the integrity of the intestinal mucosa.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15660268     DOI: 10.1007/s00384-004-0677-2

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  33 in total

Review 1.  Molecules of the extracellular matrix: potential role of collagens and glycoproteins in intestinal adaptation.

Authors:  D Schuppan; E O Riecken
Journal:  Digestion       Date:  1990       Impact factor: 3.216

2.  Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation.

Authors:  A C Rapraeger; A Krufka; B B Olwin
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

Review 3.  Proteoglycans: structures and interactions.

Authors:  L Kjellén; U Lindahl
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

4.  A major role for matrix metalloproteinases in T cell injury in the gut.

Authors:  S L Pender; S P Tickle; A J Docherty; D Howie; N C Wathen; T T MacDonald
Journal:  J Immunol       Date:  1997-02-15       Impact factor: 5.422

5.  Measuring Crohn's disease activity.

Authors:  R F Harvey; M J Bradshaw
Journal:  Lancet       Date:  1980-05-24       Impact factor: 79.321

6.  Altered glycosaminoglycan composition in reactive and neoplastic human liver.

Authors:  I Kovalszky; G Pogany; G Molnar; A Jeney; K Lapis; S Karacsonyi; A Szecseny; R V Iozzo
Journal:  Biochem Biophys Res Commun       Date:  1990-03-30       Impact factor: 3.575

7.  Disruption of sulphated glycosaminoglycans in intestinal inflammation.

Authors:  S H Murch; T T MacDonald; J A Walker-Smith; M Levin; P Lionetti; N J Klein
Journal:  Lancet       Date:  1993-03-20       Impact factor: 79.321

Review 8.  Growth factors: new 'endogenous drugs' for ulcer healing.

Authors:  S Szabo; S Kusstatscher; G Sakoulas; Z Sandor; A Vincze; M Jadus
Journal:  Scand J Gastroenterol Suppl       Date:  1995

9.  Distribution and changes of glycosaminoglycans in neoplasias of rectum.

Authors:  M E Tsara; N Papageorgacopoulou; D D Karavias; D A Theocharis
Journal:  Anticancer Res       Date:  1995 Sep-Oct       Impact factor: 2.480

10.  Highly sulfated dermatan sulfates from Ascidians. Structure versus anticoagulant activity of these glycosaminoglycans.

Authors:  M S Pavão; K R Aiello; C C Werneck; L C Silva; A P Valente; B Mulloy; N S Colwell; D M Tollefsen; P A Mourão
Journal:  J Biol Chem       Date:  1998-10-23       Impact factor: 5.157

View more
  14 in total

Review 1.  New endoscopic approach of anti-fibrotic therapy for inflammatory bowel disease.

Authors:  Kenji Suzuki; Hiroyuki Yoneyama
Journal:  Ann Transl Med       Date:  2017-04

Review 2.  Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Authors:  Israel Vlodavsky; Preeti Singh; Ilanit Boyango; Lilach Gutter-Kapon; Michael Elkin; Ralph D Sanderson; Neta Ilan
Journal:  Drug Resist Updat       Date:  2016-10-06       Impact factor: 18.500

Review 3.  Versatile role of heparanase in inflammation.

Authors:  Rachel Goldberg; Amichay Meirovitz; Nir Hirshoren; Raanan Bulvik; Adi Binder; Ariel M Rubinstein; Michael Elkin
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

4.  Mechanism of action and efficacy of RX-111, a thieno[2,3-c]pyridine derivative and small molecule inhibitor of protein interaction with glycosaminoglycans (SMIGs), in delayed-type hypersensitivity, TNBS-induced colitis and experimental autoimmune encephalomyelitis.

Authors:  Nicholas Harris; Juraj Koppel; Ferenc Zsila; Stefan Juhas; Gabriela Il'kova; Faina Yurgenzon Kogan; Orly Lahmy; Gizi Wildbaum; Nathan Karin; Regina Zhuk; Paul Gregor
Journal:  Inflamm Res       Date:  2016-01-21       Impact factor: 4.575

Review 5.  Heparanase in inflammation and inflammation-associated cancer.

Authors:  Amichay Meirovitz; Rachel Goldberg; Adi Binder; Ariel M Rubinstein; Esther Hermano; Michael Elkin
Journal:  FEBS J       Date:  2013-03-04       Impact factor: 5.542

Review 6.  Heparanase enzyme in chronic inflammatory bowel disease and colon cancer.

Authors:  Esther Hermano; Immanuel Lerner; Michael Elkin
Journal:  Cell Mol Life Sci       Date:  2012-02-14       Impact factor: 9.261

7.  The degradation of glycosaminoglycans by intestinal microflora deteriorates colitis in mice.

Authors:  Hye-Sung Lee; Song-Yi Han; Kwon-Yeul Ryu; Dong-Hyun Kim
Journal:  Inflammation       Date:  2009-02       Impact factor: 4.092

8.  Unfractionated heparin and new heparin analogues from ascidians (chordate-tunicate) ameliorate colitis in rats.

Authors:  Celso L R Belmiro; Morgana T L Castelo-Branco; Leandra M C Melim; Alberto Schanaider; Celeste Elia; Kalil Madi; Mauro S G Pavão; Heitor S P de Souza
Journal:  J Biol Chem       Date:  2009-03-02       Impact factor: 5.157

9.  Syndecan-1 deficiency promotes tumor growth in a murine model of colitis-induced colon carcinoma.

Authors:  Adi Binder Gallimidi; Gabriel Nussbaum; Esther Hermano; Barak Weizman; Amichay Meirovitz; Israel Vlodavsky; Martin Götte; Michael Elkin
Journal:  PLoS One       Date:  2017-03-28       Impact factor: 3.240

Review 10.  Gold standard for nutrition: a review of human milk oligosaccharide and its effects on infant gut microbiota.

Authors:  Shunhao Zhang; Tianle Li; Jing Xie; Demao Zhang; Caixia Pi; Lingyun Zhou; Wenbin Yang
Journal:  Microb Cell Fact       Date:  2021-05-28       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.